Adjuvant Endocrine Therapies for Premenopausal Women ...

cp418

http://www.practiceupdate.com/journalscan/26820/1/...

Adjuvant Endocrine Therapies for Premenopausal Women With HR+ HER2− Early Breast Cancer

JohnSmith

This is about the SOFT and TEXT clinical trials. Early results were announced at the December 2014 SABCS.
It's relevant for premenopausal (preM), early stage, HR+ patients.

Take away message:
- This was a pooled analysis of the TEXT (Tamoxifen and Exemestane Trial) and SOFT (Suppression of Ovarian Function Trial) studies designed to assess the absolute benefit of adjuvant endocrine therapy in 4891 premenopausal women with HR-positive, HER2-negative breast cancer.

- In patients who had high-risk breast cancers, exemestane plus ovarian function suppression resulted in an approximate 10% to 15% improvement in disease-free survival compared with tamoxifen plus ovarian function suppression. In patients with low-risk disease, all endocrine therapies appeared to confer benefit to a similar degree.

* Those in the ILC camp, still await subtype analysis comparing ILC vs. IDC outcome.